Companies to Help People Sell or Rent Out Their Health Data

Luna DNA, Nebula Genomics, and other “bio-brokers” will allow customers to make money by granting access to their genetic and personal information for research purposes.

Jun 5, 2018
Catherine Offord

ISTOCK, ALLANSWARTA growing number of companies are developing business models that center on consumers selling their genetic or health data, according to a report published yesterday (June 3) in The San Diego Union-Tribune. California-based startups Luna DNA and Nebula Genomics have built platforms to offer pay-to-access information to researchers from universities, medical institutes, and pharmaceutical companies—and turn a profit for the customer.

“There is currently little incentive for consumers to contribute their DNA and health information to a third party database,” Luna DNA explains on its website. The company’s solution, it continues, is a “community owned database that rewards individuals shares in the database for contributing their DNA and other medical information. . . . The proceeds flow back to the community like dividends as researchers pay to access the data for discovery.”

Both companies, along with similar efforts by Hong Kong–based Longenesis and Russian project Zenome, aim to meet the rising demand for biological data for everything from basic medical research to the development of drugs and diagnostics. Most incorporate the highly secure technology blockchain and will pay their customers in a cryptocurrency such as bitcoin.

Nebula Genomics, which was founded by a group of Harvard University researchers including George Church and recently partnered with Longenesis, plans for customers to undergo whole-genome sequencing, and then sell or rent those data to pharmaceutical or biotech companies at the same time as they learn more about their own DNA.

“The pitch to the average person is that you’re not just monetizing your genetic data,” Nebula cofounder Kamal Obbad told MIT Technology Review in February. “We’re also going to provide you with insights, similar to what 23andMe and do.” 

Luna DNA, meanwhile, is planning to create a database of information that people have already received from direct-to-consumer sequencing companies such as 23andMe and Customers of Luna DNA would receive compensation for allowing access to that information, explains the company’s president, Dawn Barry.

“Individuals will be rewarded when proceeds are generated through the sale of access to the data,” she tells the Union-Tribune. “Think of it like a co-op where the value comes from the data set as a whole and dividends are paid out to the individuals that contribute their genomic and health information. The more data you share, the more shares in the database you own, the greater your percentage of the proceeds.”

For now, it remains to be seen how many customers will want to take part. Blockchain technology offers better data privacy than what consumers currently have access to now, Polina Mamoshina, a researcher at biotech Insilico Medicine, which helped develop Longenesis, told Medium in February. “There is a hidden data market right now, and a lot of companies are selling our data, which is super valuable, without us knowing about it,” she says. Nevertheless, she acknowledges, “it’s hard to say whether people are going to do this.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!